Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5NET 3Thoracic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 334Carcinoma, Renal Cell 112Urinary Bladder Neoplasms 93Breast Neoplasms 55Carcinoma, Transitional Cell 48Colorectal Neoplasms 40Melanoma 39Kidney Neoplasms 39Ovarian Neoplasms 38Carcinoma, Non-Small-Cell Lung 37Neoplasms 35Neoplasm Metastasis 31Lung Neoplasms 30Sarcoma 27Pancreatic Neoplasms 25Non-Muscle Invasive Bladder Neoplasms 24Endometrial Neoplasms 23Uterine Cervical Neoplasms 21Stomach Neoplasms 21Wilms Tumor 19Carcinoma, Hepatocellular 18Esophageal Neoplasms 17Adenocarcinoma 17Squamous Cell Carcinoma of Head and Neck 16Metastatic Castration-resistant Prostate Cancer 16Head and Neck Neoplasms 16Triple Negative Breast Neoplasms 14Neuroblastoma 14Small Cell Lung Carcinoma 13Colonic Neoplasms 13

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × Genitourinary × 30 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡